Seasonal Influenza Vaccine Use by Adults in the U.S.

Detailed Survey Data Tables for the 2009-2010 Vaccination Season

Katherine M. Harris, Jürgen Maurer, Lori Uscher-Pines

ResearchPublished Jun 16, 2010

In March 2010, the RAND Corporation surveyed a nationally representative sample of noninstitutionalized adults age 18 and over (n=4,040) to collect data on the receipt of seasonal influenza vaccine in the United States. The detailed survey data presented here will inform public health officials and other stakeholders about seasonal influenza vaccination of adults shortly following the end of the vaccination season. The information on flu vaccine uptake among population groups should be of interest to those working to increase uptake among different segments of the population, including those specifically recommended for the vaccine by the Advisory Committee on Immunization Practices (ACIP) to the Centers for Disease Control and Prevention. Survey findings indicate that during the 2009–2010 vaccination season, 39 percent of all U.S. adults were vaccinated against seasonal influenza, 45 percent of adults specifically recommended for vaccination were vaccinated, and 48 percent of vaccinated adults received the vaccine at a doctor's office or medical clinic.

Topics

Document Details

  • Copyright: RAND Corporation
  • Availability: Web-Only
  • Year: 2010
  • Pages: 3
  • Document Number: OP-311/1-GSK

Citation

RAND Style Manual
Harris, Katherine M., Jürgen Maurer, and Lori Uscher-Pines, Seasonal Influenza Vaccine Use by Adults in the U.S. Detailed Survey Data Tables for the 2009-2010 Vaccination Season, RAND Corporation, OP-311/1-GSK, 2010. As of October 15, 2024: https://www.rand.org/pubs/occasional_papers/OP311z1.html
Chicago Manual of Style
Harris, Katherine M., Jürgen Maurer, and Lori Uscher-Pines, Seasonal Influenza Vaccine Use by Adults in the U.S. Detailed Survey Data Tables for the 2009-2010 Vaccination Season. Santa Monica, CA: RAND Corporation, 2010. https://www.rand.org/pubs/occasional_papers/OP311z1.html.
BibTeX RIS

This survey was conducted with the funding and support of GlaxoSmithKline (GSK) performed under the auspices of RAND Health.

This publication is part of the RAND occasional paper series. RAND occasional papers were products of RAND from 2003 to 2013 that included informed perspectives on a timely policy issue, discussions of new research methodologies, essays, papers presented at a conference, and summaries of work in progress.

This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to this product page is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial purposes. For information on reprint and reuse permissions, please visit www.rand.org/pubs/permissions.

RAND is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.